Recurrence of positive SARS-CoV-2 RNA in COVID-19: A case report

Chen, Dabiao; Xu, Wenxiong; Lei, Ziying; Huang, Zheping; Liu, Jing; Gao, Zhiliang; Peng, Liang

doi:10.1016/j.ijid.2020.03.003

Cited by 332 publications

(343 citation statements)

References 3 publications

Supporting

Mentioning

329

Contrasting

Unclassified

Order By: Relevance

“…Serological tests are in development, and they can be used if RT-PCR is not available [3]. As per the case reported by Chen et al, the oropharyngeal swab test of COVID-19 RNA turned positive even during the convalescence period in a confirmed case; it emphasizes the significance of active surveillance of COVID-19 RNA for inactivity assessment [28].…”

Section: Laboratory Testingmentioning

confidence: 76%

COVID-19, Modern Pandemic: A Systematic Review From Front-Line Health Care Providers’ Perspective

et al. 2020

View full text Add to dashboard Cite

Coronavirus disease 2019 caused infection in 168,000 cases worldwide in about 148 countries and killed more than 6,610 people around the world as of March 16, 2020, as per the World Health Organization (WHO). Compared to severe acute respiratory syndrome and Middle East respiratory syndrome, there is the rapid transmission, long incubation period, and disease containment is becoming extremely difficult. The main aim of this systematic review is to provide a comprehensive clinical summary of all the available data from high-quality research articles relevant to the epidemiology, demographics, trends in hospitalization and outcomes, clinical signs and symptoms, diagnostic methods and treatment methods of COVID-19, thus increasing awareness in health care providers. We also discussed various preventive measures to combat COVID-19 effectively. A systematic and protocol-driven approach is needed to contain this disease, which was declared as a global pandemic on March 11, 2020, by the WHO. Literature Search MethodsWe conducted a systematic search of published articles from PubMed, google scholar databases and in-press literature from google search engine through snowballing. There were two independent reviewers, each focusing on COVID-19, novel coronavirus (nCoV), SARS and MERS, and third independent reviewer to resolve any conflicting article of interest. We used the keywords as mentioned above and after stringent exclusion criteria, a total of 58 articles, including reports from the trusted newspapers and websites. Most of the articles were single case reports, multiple case studies and systematic reviews (11 retrospective studies, one meta-analysis, three systematic reviews, six case series, five case reports, five newspapers, 24 science research articles, and rest 3 reference's from official websites). EpidemiologyThe initial cases were strongly associated with the Huanan seafood market, in which exotic animals were sold for food [3]. According to Lu et al, the virus (termed SARS-CoV-2) shares 88% sequence identity to two coronaviruses found in bats, bat-

show abstract

Section: Laboratory Testingmentioning

confidence: 76%

COVID-19, Modern Pandemic: A Systematic Review From Front-Line Health Care Providers’ Perspective

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Currently, a tremendous amount of research is in progress to develop a vaccine against COVID-19. However, vaccine development is time consuming process, and the newly introduced vaccine will require several safety evaluations [4]. According to estimates, a vaccine against COVID-19 may take more than a year to become available [108].…”

Section: Potential Therapeutics and Treatment For Covid-19mentioning

confidence: 99%

“…Sneezing, runny nose, and symptoms similar to the common cold are observed in only 5% of patients. About 2% to 10% of patients have shown diarrhea like symptoms [3,4]. The mortality rate of COVID-19 is 4.5% to 6%, which is less than that of SARS (severe acute respiratory syndrome), which has a mortality rate of 9.6%, and less than that of MERS (Middle East respiratory syndrome), up to 34.4% deaths.…”

Section: Introductionmentioning

confidence: 99%

Origin, Potential Therapeutic Targets and Treatment for Coronavirus Disease (COVID-19)

et al. 2020

View full text Add to dashboard Cite

The ongoing episode of coronavirus disease 19 has imposed a serious threat to global health and the world economy. The disease has rapidly acquired a pandemic status affecting almost all populated areas of the planet. The causative agent of COVID-19 is a novel coronavirus known as SARS-CoV-2. The virus has an approximate 30 kb single-stranded positive-sense RNA genome, which is 74.5% to 99% identical to that of SARS-CoV, CoV-pangolin, and the coronavirus the from horseshoe bat. According to available information, SARS-CoV-2 is inferred to be a recombinant virus that originated from bats and was transmitted to humans, possibly using the pangolin as the intermediate host. The interaction of the SARS-CoV-2 spike protein with the human ACE2 (angiotensin-converting enzyme 2) receptor, and its subsequent cleavage by serine protease and fusion, are the main events in the pathophysiology. The serine protease inhibitors, spike protein-based vaccines, or ACE2 blockers may have therapeutic potential in the near future. At present, no vaccine is available against COVID-19. The disease is being treated with antiviral, antimalarial, anti-inflammatory, herbal medicines, and active plasma antibodies. In this context, the present review article provides a cumulative account of the recent information regarding the viral characteristics, potential therapeutic targets, treatment options, and prospective research questions.

show abstract

“…1 While there are reports of patients who have been discharged and subsequently report positive RT-PCR, no study has attempted to describe the magnitude and significance of this issue at the country level. 2,3,4,5 This phenomenon which we term 're-positive' could complicate the management of COVID-19 patients.…”

Section: Introductionmentioning

confidence: 99%

Probable causes and risk factors for positive SARS-CoV-2 test in recovered patients: Evidence from Brunei Darussalam

Wong

Koh

Momin

et al. 2020

Preprint

View full text Add to dashboard Cite

We report findings of a national study in Brunei Darussalam indicating that one in five recovered patients subsequently test positive again for SARS-CoV-2-this risk is nearly three times higher in older patients (age 53 and above) than younger ones (below age 53). Review of clinical and epidemiological records do not support reinfection or reactivation as likely causes of the 're-positive' observation. Instead, prolonged but intermittent viral shedding is the most probable explanation. We discuss the implications of these findings for infection control and clinical practice.

show abstract

Recurrence of positive SARS-CoV-2 RNA in COVID-19: A case report

Cited by 332 publications

References 3 publications

COVID-19, Modern Pandemic: A Systematic Review From Front-Line Health Care Providers’ Perspective

COVID-19, Modern Pandemic: A Systematic Review From Front-Line Health Care Providers’ Perspective

Origin, Potential Therapeutic Targets and Treatment for Coronavirus Disease (COVID-19)

Probable causes and risk factors for positive SARS-CoV-2 test in recovered patients: Evidence from Brunei Darussalam

Contact Info

Product

Resources

About